淋巴肿瘤包括各类淋巴瘤和多发性骨髓瘤的精确诊断、规范化治疗及细胞免疫治疗。主要研究方向为淋巴肿瘤CAR-T细胞治疗基础及转化研究。

参与多项国家自然科学基金及中国医学科学院创新工程项目。

1. Hesong Zou#, Wei Liu#, Xiaojuan Wang#, et al. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. J Immunother Cancer. 2024 Mar 4;12(3):e008450. 

2. Wei Liu#, Wei Liu#, Hesong Zou#, et al. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma. J Immunother Cancer. 2024 Apr 16;12(4):e008857. 

3. Hesong Zou#, Wei Liu#, Yi Wang, et al. Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features. Chin Med J (Engl). 2024 Jul 5;137(13):1620-1622.

4. Huimin Liu#, Hesong Zou#, Dandan Shan, et al. Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes. Cancer Med. 2024 Jan;13(2):e6965.